Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123728715 | 12372871 | 5 | F | 20160801 | 20160516 | 20160805 | EXP | US-PFIZER INC-2016258669 | PFIZER | 74.00 | YR | M | Y | 82.55000 | KG | 20160805 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123728715 | 12372871 | 1 | PS | NEURONTIN | GABAPENTIN | 1 | Oral | 1200 MG, DAILY (ONE IN THE MORNING, ONE AT NOON, AND TWO AT BEDTIME) | 20235 | CAPSULE, HARD | TID | ||||||||
| 123728715 | 12372871 | 2 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 300 MG, 4X/DAY | 20235 | 300 | MG | CAPSULE, HARD | QID | ||||||
| 123728715 | 12372871 | 3 | SS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, 4X/DAY | 20235 | 300 | MG | QID | |||||||
| 123728715 | 12372871 | 4 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Oral | 100 UG, 1X/DAY | 0 | 100 | UG | TABLET | QD | ||||||
| 123728715 | 12372871 | 5 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | Oral | 100 MG, 1X/DAY (AT BEDTIME) | 0 | 100 | MG | TABLET | QD | ||||||
| 123728715 | 12372871 | 6 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | 0 | TABLET | |||||||||||
| 123728715 | 12372871 | 7 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | TABLET | QD | ||||||
| 123728715 | 12372871 | 8 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 2 MG, DAILY (0.5 MG ONE IN THE MORNING, ONE AT NOON, TWO AT BEDTIME) | 0 | 2 | MG | TABLET | |||||||
| 123728715 | 12372871 | 9 | C | LORAZEPAM. | LORAZEPAM | 1 | 0.5 MG, 4X/DAY | 0 | .5 | MG | TABLET | QID | |||||||
| 123728715 | 12372871 | 10 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | TABLET | |||||||||||
| 123728715 | 12372871 | 11 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | 0.5 MG, DAILY | 0 | .5 | MG | TABLET | |||||||
| 123728715 | 12372871 | 12 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 1 MG, DAILY | 0 | 1 | MG | TABLET | ||||||||
| 123728715 | 12372871 | 13 | C | PROBIOTICS | PROBIOTICS NOS | 1 | Oral | 2 DF, DAILY | 0 | 2 | DF | ||||||||
| 123728715 | 12372871 | 14 | C | STOOL SOFTENER | DOCUSATE CALCIUM | 1 | Oral | 200 MG, DAILY (TWO IN THE MORNING AND TWO AT NIGHT) | 0 | TABLET | BID | ||||||||
| 123728715 | 12372871 | 15 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Oral | 2 DF, DAILY | 0 | 2 | DF | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123728715 | 12372871 | 1 | Nerve injury |
| 123728715 | 12372871 | 2 | Diabetic neuropathy |
| 123728715 | 12372871 | 3 | Diabetic neuropathy |
| 123728715 | 12372871 | 4 | Hypothyroidism |
| 123728715 | 12372871 | 5 | Insomnia |
| 123728715 | 12372871 | 6 | Depression |
| 123728715 | 12372871 | 7 | Nephropathy |
| 123728715 | 12372871 | 8 | Nerve injury |
| 123728715 | 12372871 | 9 | Dizziness |
| 123728715 | 12372871 | 10 | Anxiety |
| 123728715 | 12372871 | 11 | Renal disorder |
| 123728715 | 12372871 | 12 | Diabetes mellitus |
| 123728715 | 12372871 | 14 | Malaise |
| 123728715 | 12372871 | 15 | Renal pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123728715 | 12372871 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123728715 | 12372871 | Affective disorder | |
| 123728715 | 12372871 | Burning sensation | |
| 123728715 | 12372871 | Condition aggravated | |
| 123728715 | 12372871 | Depression | |
| 123728715 | 12372871 | Diabetic neuropathy | |
| 123728715 | 12372871 | Dizziness | |
| 123728715 | 12372871 | Fatigue | |
| 123728715 | 12372871 | Infection | |
| 123728715 | 12372871 | Lymphadenopathy | |
| 123728715 | 12372871 | Muscle fatigue | |
| 123728715 | 12372871 | Myalgia | |
| 123728715 | 12372871 | Overdose | |
| 123728715 | 12372871 | Pain in extremity | |
| 123728715 | 12372871 | Peripheral swelling | |
| 123728715 | 12372871 | Pneumonia | |
| 123728715 | 12372871 | Product use issue | |
| 123728715 | 12372871 | Pyrexia | |
| 123728715 | 12372871 | Rash | |
| 123728715 | 12372871 | Renal impairment | |
| 123728715 | 12372871 | Speech disorder | |
| 123728715 | 12372871 | Suicidal behaviour | |
| 123728715 | 12372871 | Suicidal ideation | |
| 123728715 | 12372871 | Tuberculosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123728715 | 12372871 | 13 | 2014 | 0 | ||
| 123728715 | 12372871 | 15 | 2012 | 0 |